Abstract
Background: Wilson disease is genetic disorder of copper metabolism which causes hepatic & neurologic manifestations mainly. Chelation therapy specially penicillamine is given as first line treatment in children with symptomatic wilson disease. Objective: To assess the safety & the clinical outcome of treatment with low dose penicillamine in Neurologic wilson disease
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
